Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family

Cediranib is a potent inhibitor of the VEGF receptor (VEGFR)-2 and VEGFR-3 tyrosine kinases. This study assessed the activity of cediranib against the VEGFR-1 tyrosine kinase and the platelet-derived growth factor receptor (PDGFR)-associated kinases c-Kit, PDGFR-α, and PDGFR-β. Cediranib inhibited V...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer therapeutics 2011-05, Vol.10 (5), p.861-873
Main Authors: Brave, Sandra R, Ratcliffe, Kirsty, Wilson, Zena, James, Neil H, Ashton, Sue, Wainwright, Anna, Kendrew, Jane, Dudley, Philippa, Broadbent, Nicola, Sproat, Graham, Taylor, Sian, Barnes, Claire, Silva, Jeffrey C, Farnsworth, Charles L, Hennequin, Laurent, Ogilvie, Donald J, Jürgensmeier, Juliane M, Shibuya, Masabumi, Wedge, Stephen R, Barry, Simon T
Format: Article
Language:English
Subjects:
Animals
Cell Line, Tumor
Cell Proliferation - drug effects
Cercopithecus aethiops
COS Cells
fms-Like Tyrosine Kinase 3 - antagonists & inhibitors
HEK293 Cells
Humans
Ligands
Lung - drug effects
Mice
Mice, Nude
NIH 3T3 Cells
Phosphorylation - drug effects
Platelet-Derived Growth Factor - metabolism
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Proto-Oncogene Proteins c-kit - antagonists & inhibitors
Quinazolines - chemistry
Quinazolines - pharmacology
Rats
Receptor Protein-Tyrosine Kinases - antagonists & inhibitors
Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors
Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
Signal Transduction - drug effects
Stem Cell Factor - metabolism
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cediranib is a potent inhibitor of the VEGF receptor (VEGFR)-2 and VEGFR-3 tyrosine kinases. This study assessed the activity of cediranib against the VEGFR-1 tyrosine kinase and the platelet-derived growth factor receptor (PDGFR)-associated kinases c-Kit, PDGFR-α, and PDGFR-β. Cediranib inhibited VEGF-A-stimulated VEGFR-1 activation in AG1-G1-Flt1 cells (IC(50) = 1.2 nmol/L). VEGF-A induced greatest phosphorylation of VEGFR-1 at tyrosine residues Y1048 and Y1053; this was reversed by cediranib. Potency against VEGFR-1 was comparable with that previously observed versus VEGFR-2 and VEGFR-3. Cediranib also showed significant activity against wild-type c-Kit in cellular phosphorylation assays (IC(50) = 1-3 nmol/L) and in a stem cell factor-induced proliferation assay (IC(50) = 13 nmol/L). Furthermore, phosphorylation of wild-type c-Kit in NCI-H526 tumor xenografts was reduced markedly following oral administration of cediranib (≥1.5 mg/kg/d) to tumor-bearing nude mice. The activity of cediranib against PDGFR-β and PDGFR-α was studied in tumor cell lines, vascular smooth muscle cells (VSMC), and a fibroblast line using PDGF-AA and PDGF-BB ligands. Both receptor phosphorylation (IC(50) = 12-32 nmol/L) and PDGF-BB-stimulated cellular proliferation (IC(50) = 32 nmol/L in human VSMCs; 64 nmol/L in osteosarcoma cells) were inhibited. In vivo, ligand-induced PDGFR-β phosphorylation in murine lung tissue was inhibited by 55% following treatment with cediranib at 6 mg/kg but not at 3 mg/kg or less. In contrast, in C6 rat glial tumor xenografts in mice, ligand-induced phosphorylation of both PDGFR-α and PDGFR-β was reduced by 46% to 61% with 0.75 mg/kg cediranib. Additional selectivity was showed versus Flt-3, CSF-1R, EGFR, FGFR1, and FGFR4. Collectively, these data indicate that cediranib is a potent pan-VEGFR kinase inhibitor with similar activity against c-Kit but is significantly less potent than PDGFR-α and PDGFR-β.
ISSN:1535-7163
1538-8514
DOI:10.1158/1535-7163.MCT-10-0976